True or false: A blood transfusion replaces a specific blood component or substance, rather than blood in general.
1 Blood Products and Transfusion Safety Online Quiz Questions
Use this free practice quiz with 20 questions to review 1 Blood Products and Transfusion Safety, test your knowledge, and prepare for your next test or exam.
A patient has symptomatic anemia that is impairing oxygen delivery but is not bleeding. Which product most directly addresses the problem?
- A
Red blood cells
- B
Platelets
- C
Fresh frozen plasma
- D
Cryoprecipitate
A clinician considers plasma for an unrelated purpose. Complete the statement: Plasma is not a .
A routine platelet product requires temperature-controlled storage with gentle, continuous agitation. What is the usual storage temperature range?
A patient has critical bleeding associated with low fibrinogen. Which product most directly provides concentrated fibrinogen?
- A
Red blood cells
- B
Platelets
- C
Fresh frozen plasma
- D
Cryoprecipitate
A patient has an abnormal platelet result. Select all statements that correctly guide consideration of platelet transfusion.
- A
Platelet transfusion may be used to treat or prevent bleeding when platelet numbers are low.
- B
Impaired platelet function can be relevant even when considering platelet transfusion.
- C
A low platelet count by itself always establishes the need for transfusion.
- D
Platelets are indicated only when a patient is actively bleeding.
True or false: Once frozen plasma or cryoprecipitate has been thawed, it may be refrozen whenever it has not yet been used.
- A
True
- B
False
In the United States, red blood cells are commonly refrigerated within what temperature range?
During the required bedside check, select all actions that support safe verification before a transfusion begins.
- A
Match the patient and product identifiers.
- B
Verify the component and compatibility information.
- C
Check the expiration and any special product requirements.
- D
Proceed if a mismatch is minor and can be corrected after starting.
- E
Stop and resolve any discrepancy before administration.
Before thawing, frozen plasma and cryoprecipitate are kept at the temperature specified for the product.
A patient develops chills and breathing difficulty during a transfusion. Describe the immediate response and the key actions that should follow.
A clinician is considering a plasma-derived medicinal product, such as an immunoglobulin or clotting-factor concentrate. Which principle should guide its use?
- A
They can be prescribed and handled exactly like any transfusable blood component.
- B
They are general-purpose substitutes for whichever blood component is unavailable.
- C
They have product-specific indications and their own prescribing and handling instructions.
- D
They are used only to expand blood volume.
A product has been prepared for a patient. Before administration, which approach best confirms that transfusion is appropriate and authorized?
- A
Start the transfusion if a laboratory value is abnormal, even if the indication and decision process have not been confirmed.
- B
Confirm the order and indication, consent or documented decision process, and any required special product attributes.
- C
Use the product that is easiest to obtain, then reassess whether it addresses the patient's need.
- D
Rely on the patient's preference alone without confirming the clinical need.
A stable, nonbleeding adult has symptomatic anemia and is prescribed red blood cells. Under the common approach described, how many units are usually given before reassessment?
A blood-storage refrigerator is set to the lower endpoint of the common U.S. storage range for red blood cells. What is that temperature?
A service stores routine platelets at 20–24 °C without agitation. This matches the usual storage and handling conditions for routine platelets.
- A
True
- B
False
A patient has symptomatic anemia impairing oxygen delivery but is not bleeding. Which product most directly addresses the problem?
- A
Plasma
- B
Red blood cells
- C
Platelets
- D
Cryoprecipitate
A patient is bleeding and has a clinically significant clotting-factor deficiency. A specific factor treatment is unsuitable or unavailable. Which plan best matches the described use of plasma?
- A
Use plasma as a general volume expander.
- B
Use plasma as a general nutrition product.
- C
Consider plasma for bleeding or bleeding risk with a significant clotting-factor deficiency when specific factor treatment is unsuitable or unavailable.
- D
Use plasma to replace low fibrinogen in every situation.
A patient develops chills during a transfusion. What is the priority response?
- A
Slow the transfusion and observe for several minutes.
- B
Finish the current component, then report the chills.
- C
Discard the bag and tubing before seeking advice.
- D
Stop the transfusion, assess the patient, call for clinical help, and follow the reaction protocol.
An issued blood component is delayed and its storage conditions are uncertain. What should the care team do before deciding whether it can be transfused?
- A
Inspect the component’s appearance and use it if it looks normal.
- B
Contact the transfusion service for guidance.
- C
Return it to any refrigerator until it is needed.
- D
Use it if the original order is still active.